Glenn Batchelder

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

The Michael J. Fox Foundation for Parkinson's Research engages in finding a cure for Parkinson's disease within the decade through funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's. It is delivering patients better treatments and, ultimately, a cure for Parkinson's disease. It developed a targeted approach to research funding that helps them identify and prioritize the patient-relevant science. The company was founded by Michael J. Fox and Deborah W. Brooks in 2000 and is headquartered in New York, NY.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.